The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
Clinical trial NCT07724951 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07724951
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2026-07-31
- Primary completion
- 2028-07-31
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.